{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:41:19Z","timestamp":1773772879060,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T00:00:00Z","timestamp":1413244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["BMBF01 EO1004"],"award-info":[{"award-number":["BMBF01 EO1004"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.beem.2014.10.003","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T14:18:50Z","timestamp":1413469130000},"page":"195-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Fabry disease and the heart"],"prefix":"10.1016","volume":"29","author":[{"given":"Nora","family":"Seydelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"St\u00f6rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.10.003_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.beem.2014.10.003_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.gene.2013.09.058","article-title":"Novel alpha-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease","volume":"535","author":"Duro","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.beem.2014.10.003_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2014.10.003_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.10.003_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.beem.2014.10.003_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib7","first-page":"38","article-title":"Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy","volume":"22","author":"Morrissey","year":"2011","journal-title":"Cardiovasc J Afr"},{"key":"10.1016\/j.beem.2014.10.003_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.10.003_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.10.003_bib10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"Jama"},{"key":"10.1016\/j.beem.2014.10.003_bib11","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib13","series-title":"Fabry disease: alpha galactosidase A deficienca. The metabolic and molecular bases of inherited disease","first-page":"1741","author":"Desnick","year":"1995"},{"key":"10.1016\/j.beem.2014.10.003_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","article-title":"Manifestations of Fabry disease in placental tissue","volume":"29","author":"Vedder","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"Suppl. A","key":"10.1016\/j.beem.2014.10.003_bib15","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0149-2918(07)80115-9","article-title":"Fabry disease model: a rational approach to the management of Fabry disease","volume":"29","author":"Wanner","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.beem.2014.10.003_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","article-title":"Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells","volume":"95","author":"Shen","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.10.003_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2014.10.003_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2014.10.003_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur Heart J"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2014.10.003_bib20","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.beem.2014.10.003_bib21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.beem.2014.10.003_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"Qjm"},{"key":"10.1016\/j.beem.2014.10.003_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.beem.2014.10.003_bib25","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10545-006-0360-6","article-title":"Extracellular matrix turnover and disease severity in Anderson-Fabry disease","volume":"30","author":"Shah","year":"2007","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.10.003_bib27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.echo.2013.08.024","article-title":"Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy","volume":"26","author":"Boyd","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.beem.2014.10.003_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.beem.2014.10.003_bib29","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2014.10.003_bib30","first-page":"831","article-title":"Nomen est omen. Fabry disease","volume":"9","author":"Weidemann","year":"2008","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.beem.2014.10.003_bib31","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib32","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehm454","article-title":"A\u00a0new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium","volume":"28","author":"Weidemann","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kramer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib34","first-page":"50","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.beem.2014.10.003_bib35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2014.10.003_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-med-090910-085119","article-title":"The Fabry cardiomyopathy: models for the cardiologist","volume":"62","author":"Weidemann","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.beem.2014.10.003_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.12.022","article-title":"Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge","volume":"123","author":"Weidemann","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2014.10.003_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.echo.2006.08.023","article-title":"Non-doppler two-dimensional strain imaging by echocardiography\u2013from technical considerations to clinical applications","volume":"20","author":"Perk","year":"2007","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.beem.2014.10.003_bib39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.beem.2014.10.003_bib40","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.10.003_bib41","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A\u00a0metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.beem.2014.10.003_bib42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.beem.2014.10.003_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.10.003_bib44","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1021\/pr301200e","article-title":"The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients","volume":"12","author":"Manwaring","year":"2013","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.beem.2014.10.003_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes-lyso-Gb3 defines fabry disease","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.beem.2014.10.003_bib46","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2014.10.003_bib47","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2014.10.003_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.beem.2014.10.003_bib50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","article-title":"Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry","volume":"12","author":"Watt","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2014.10.003_bib51","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.113.002799","article-title":"Progression of Fabry cardiomyopathy despite enzyme replacement therapy","volume":"128","author":"Pieroni","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2014.10.003_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A\u00a0retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.10.003_bib54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1590\/S1807-59322010000700012","article-title":"Anti-hypertensive drugs have different effects on ventricular hypertrophy regression","volume":"65","author":"Ferreira Filho","year":"2010","journal-title":"Clin Sao Paulo"},{"key":"10.1016\/j.beem.2014.10.003_bib55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0002-8703(97)70095-4","article-title":"Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension","volume":"134","author":"Lombardo","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2014.10.003_bib56","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.beem.2014.10.003_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1651-2227.2007.00215.x","article-title":"Optimization of concomitant medication in Fabry cardiomyopathy","volume":"96","author":"Close","year":"2007","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.beem.2014.10.003_bib58","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"Zipes","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2014.10.003_bib59","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/jama.1983.03330400029012","article-title":"Amiodarone phenocopy of Fabry's keratopathy","volume":"249","author":"Whitley","year":"1983","journal-title":"Jama"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:48:28Z","timestamp":1761497308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1521690X14001250"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.10.003","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease and the heart","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}